Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H23NO |
| Molecular Weight | 257.3706 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=CC=C(O)C=C34
InChI
InChIKey=JAQUASYNZVUNQP-USXIJHARSA-N
InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m0/s1
| Molecular Formula | C17H23NO |
| Molecular Weight | 257.3706 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Levorphanol, brand name Levo-Dromoran, is an opioid medication used to treat moderate to severe pain. Levorphanol is indicated for the management of moderate to severe pain where an opioid analgesic
is appropriate. It is a potent synthetic opioid mu-receptor agonist similar in action to morphine. Like other opioid
mu-receptor agonists, it is believed to act at receptors in both the brain and spinal cord to alter the transmission
and perception of pain. The onset and peak analgesic effects following administration of levorphanol are similar to
morphine when administered at equal analgesic doses. Levorphanol produces a degree of respiratory depression
similar to that produced by morphine at equal analgesic doses, and like many opioid mu-receptor agonists,
levorphanol produces euphoria or has a positive effect on mood in many individuals.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL233 |
0.21 nM [Ki] | ||
Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17039381 |
4.2 nM [Ki] | ||
Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17039381 |
2.3 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Levorphanol Tartrate Approved UseLevorphanol Tartrate Tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Launch Date1953 |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator​
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes [IC50 11.5 uM] | ||||
| yes [IC50 >50 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes | ||||
| yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Acute pain management in children. | 2010-07-15 |
|
| Preoperative oral dextromethorphan does not reduce pain or morphine consumption after open cholecystectomy. | 2010-02 |
|
| Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. | 2010-01-14 |
|
| Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan. | 2010-01 |
|
| Chronic pain: levorphanol, methadone, and the N-methyl-D-aspartate receptor. | 2009-09 |
|
| Preoperative oral dextromethorphan does not reduce pain or morphine consumption after open cholecystectomy. | 2009-07 |
|
| A retrospective study on the impact of comorbid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients. | 2009-06-30 |
|
| Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells. | 2009-06-07 |
|
| Effects of environmental enrichment on sensitivity to mu, kappa, and mixed-action opioids in female rats. | 2008-07-05 |
|
| Challenges in using opioids to treat pain in persons with substance use disorders. | 2008-06 |
|
| An evaluation of the genotoxicity of the antitussive drug Dextromethorphan. | 2008-04 |
|
| Opioid pharmacology. | 2008-03 |
|
| Opiates and elderly: use and side effects. | 2008 |
|
| Levorphanol revisited. | 2007-12 |
|
| Chronic morphine treatment up-regulates mu opioid receptor binding in cells lacking filamin A. | 2007-10-26 |
|
| Morphine reduces local cytokine expression and neutrophil infiltration after incision. | 2007-10-02 |
|
| Current aproach to cancer pain management: Availability and implications of different treatment options. | 2007-06 |
|
| Synthesis and pharmacological evaluation of 6,7-indolo/thiazolo-morphinans--further SAR of levorphanol. | 2007-05-31 |
|
| Can levorphanol be used like methadone for intractable refractory pain? | 2007-04 |
|
| High-affinity carbamate analogues of morphinan at opioid receptors. | 2007-03-15 |
|
| Levorphanol: the forgotten opioid. | 2007-03 |
|
| Cholesterol reduction by methyl-beta-cyclodextrin attenuates the delta opioid receptor-mediated signaling in neuronal cells but enhances it in non-neuronal cells. | 2007-02-15 |
|
| Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior. | 2007-02 |
|
| The effect of opiates on the activity of human placental aromatase/CYP19. | 2007-01-15 |
|
| Does purity of supplements count? | 2007-01 |
|
| Chronic exercise decreases sensitivity to mu opioids in female rats: correlation with exercise output. | 2006-09 |
|
| Restless legs syndrome: diagnosis and review of management options. | 2006-06 |
|
| Opioid peptides and receptors in joint tissues: study in the rat. | 2006-06 |
|
| Over-the-counter cold medications-postmortem findings in infants and the relationship to cause of death. | 2005-10 |
|
| Social and environmental influences on opioid sensitivity in rats: importance of an opioid's relative efficacy at the mu-receptor. | 2005-08 |
|
| Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. | 2005-07 |
|
| Discriminative stimulus effects of acute morphine followed by naltrexone in the squirrel monkey: a further characterization. | 2005-07 |
|
| [Fundamentals of modern treatment of myopia]. | 2005 |
|
| Antidepressant-like effect of tramadol and its enantiomers in reserpinized mice: comparative study with desipramine, fluvoxamine, venlafaxine and opiates. | 2004-09 |
|
| Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. | 2004-05 |
|
| 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors. | 2004-01-01 |
|
| Differential effects of agonists on adenylyl cyclase superactivation mediated by the kappa opioid receptors: adenylyl cyclase superactivation is independent of agonist-induced phosphorylation, desensitization, internalization, and down-regulation. | 2003-12 |
|
| The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the mu-opioid receptor. | 2003-11 |
|
| Sensitivity to the effects of opioids in rats with free access to exercise wheels: mu-opioid tolerance and physical dependence. | 2003-08 |
|
| Opioids ease neuropathic pain, but... | 2003-05 |
|
| Interactions between opioids and cocaine on locomotor activity in rats: influence of an opioid's relative efficacy at the mu receptor. | 2003-05 |
|
| Opioids and chronic neuropathic pain. | 2003-03-27 |
|
| Oral opioid therapy for chronic peripheral and central neuropathic pain. | 2003-03-27 |
|
| Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. | 1995-09 |
|
| Differential effects of morphinan drugs on haloperidol-induced catalepsy in rats: a comparative study with an N-methyl-D-aspartate antagonist. | 1991-03-01 |
|
| Baclofen-induced catatonia. | 1986-12 |
|
| Effect of prolyl-leucyl-glycinamide and alpha-melanocyte-stimulating hormone on levorphanol-induced analgesia, tolerance and dependence. | 1984-06-25 |
|
| Relative cataleptic potency of narcotic analgesics, including 3,6-dibutanoylmorphine and 6-monoacetylmorphine. | 1984 |
|
| Prostaglandin hyperalgesia, V: a peripheral analgesic receptor for opiates. | 1982-01 |
|
| Comparison of opioid agonists in maintaining responding and in suppressing morphine withdrawal in rhesus monkeys. | 1981 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/levorphanol.html
Usual Adult Dose for Light Sedation
Premedication for Anesthesia:
1 to 2 mg IM or subcutaneously, administered 60 to 90 minutes before surgery. Older or debilitated patients usually require less drug. Two mg of levorphanol is approximately equivalent to 10 to 15 mg of morphine or 100 mg of meperidine.
Usual Adult Dose for Pain
IV: 1 mg every 3 to 6 hours as needed.
IM or subcutaneous: 1 to 2 mg every 6 to 8 hours as needed.
Oral: 2 mg every 6 to 8 hours as needed.
May be increased to 3 mg every 6 to 8 hours.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7284815
Levorphanol (5-100 uM), consistently depressed the responses evoked by the putative inhibitory amino acid neurotransmitters glycine and beta-alanine but not GABA in cultured mouse spinal cord neurons.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:23:57 GMT 2025
by
admin
on
Wed Apr 02 09:23:57 GMT 2025
|
| Record UNII |
27618J1N2X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
||
|
DEA NO. |
9220
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
||
|
NDF-RT |
N0000175684
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
||
|
LIVERTOX |
NBK547967
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
||
|
NDF-RT |
N0000175690
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
||
|
NCI_THESAURUS |
C1506
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
77-07-6
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | |||
|
3349
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | |||
|
6378
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | RxNorm | ||
|
CHEMBL592
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | |||
|
27618J1N2X
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | |||
|
LEVORPHANOL
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | |||
|
27618J1N2X
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | |||
|
91
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | |||
|
C61810
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | |||
|
1574
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | |||
|
DB00854
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | |||
|
DTXSID3023213
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | |||
|
5359272
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | |||
|
m6794
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000082303
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | |||
|
7595
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | |||
|
D007981
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | |||
|
SUB08490MIG
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY | |||
|
201-002-6
Created by
admin on Wed Apr 02 09:23:57 GMT 2025 , Edited by admin on Wed Apr 02 09:23:57 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
Ki
|
||
|
TARGET -> INHIBITOR |
NON-COMPETITIVE
Ki
|
||
|
TARGET -> AGONIST |
Ki
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> AGONIST |
Ki
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| CLEARANCE | PHARMACOKINETIC |
|
||||
| CSF/PLASMA RATIO | PHARMACOKINETIC |
|
|
|||
| Biological Half-life | PHARMACOKINETIC |
|
||||
| Volume of Distribution | PHARMACOKINETIC |
|
||||